Filing identity and reporting period
Important mismatch: The supplied filing is for Trail One, Inc., not Citius Pharmaceuticals, Inc. It reports the fiscal year ended September 30, 2012; despite the request metadata saying “2012 Q4,” the filing presents annual financial statements. The filing cover also marks the quarterly-report box, although it identifies the fiscal year ended September 30, 2012.
Business context and financial results
Trail One was a development-stage company planning to sell customized aluminum automobile license-plate frames. It had not begun production or sales and reported no revenue in fiscal 2012 or 2011. Its planned manufacturing arrangement with Advanced Precision Manufacturing Inc. was not yet covered by an agreement.
- Fiscal 2012 net loss was $22,006, versus $26,341 for fiscal 2011, based on the audited statements. The filing’s MD&A gives a different 2011 comparison in one passage; see investor verification items.
- Fiscal 2012 operating expenses were $19,618: general and administrative costs of $4,059 and professional fees of $15,559. Interest expense was $2,388. No income-tax provision was reported.
- Gross margin is not meaningful because there were no sales. Basic and diluted loss per share were each reported as ($0.00); weighted-average shares were 18,000,000.
- At September 30, 2012, cash was $135, total current liabilities were $45,982, and the working-capital deficit was $45,847. Accumulated deficit was $63,847.
- Current liabilities included $21,693 of related-party notes and $17,047 of non-related-party notes, both due on demand and bearing 8% interest, plus accrued interest and expenses. Cash interest paid during the year was $0.
- Cash used in operating activities was $20,324; financing activities provided $20,247. Ending cash declined by $77 from $212 at September 30, 2011.
Changes, outlook, and key risks
The annual loss narrowed from fiscal 2011, while cash fell to $135 and current liabilities increased from $24,053 to $45,982. The company said it expected continuing losses and insufficient revenue to cover expenses during the next 12 months. It estimated that $75,000 would be needed to advance its business plan, but had no committed financing arrangement; a potential loan from CEO Ralph Montrone was discussed without an agreement. Management said it might seek equity, debt, private, or bank financing, and warned that failure to obtain funding could force it to curtail or cease operations.
The auditor’s report included a going-concern emphasis, stating that losses and a net capital deficiency raised substantial doubt about the company’s ability to continue. The financial statements were not adjusted for possible outcomes of that uncertainty. Management also disclosed ineffective disclosure controls, citing the lack of an independent board or audit committee and inadequate segregation of duties. Other significant risks included dependence on the CEO, reliance on an intended manufacturer without a contract, competition, potential shareholder dilution, and the absence of an established public trading market. No material legal proceedings were identified.
Investor verification priorities
- Confirm the issuer and period: this document is Trail One’s fiscal 2012 annual report, not a Citius Pharmaceuticals filing or a quarterly report.
- Reconcile the 2011 net-loss comparison: the audited statements show a fiscal-year loss of $26,341 and an inception-to-September 2011 accumulated loss of $41,841; one MD&A passage describes $41,841 as the 2011 comparison.
- Verify the reported financing need, available cash, and status of any subsequent financing. The filing notes a $600 unsecured loan received January 4, 2013.
- Assess demand and execution evidence: no product had been manufactured or sold, and the intended manufacturer relationship was not formalized.
- Review related-party and third-party demand loans, governance and control weaknesses, ownership concentration, and the lack of a liquid trading market.